Topical Therapy I Corticosteroids and Vitamin D Analogues
Topical Therapy II Retinoids Immunomodulators and Others
Ultraviolet Therapy for Psoriasis
TCell Targeted Therapy Alefacept and Efalizumab
Research Pipeline I Topical Therapies
Research Pipeline II Oral Therapeutics
Research Pipeline III Biologic Therapies
Pediatric Psoriasis
Psoriasis and Comorbidities
Summary of Published Treatment Guidelines
Appendix 1
Laser Therapy for Psoriasis
Traditional Systemic Therapy I Methotrexate and Cyclosporine
Traditional Systemic Therapy II Retinoids and Others
Etanercept
Adalimumab
Infliximab and Golimumab
Ustekinumab
Appendix 2
Appendix 3
Appendix 4
Appendix 5
Index
It has become increasingly clear that psoriatic disease, both of the skin and joints, can be a significant diagnostic and therapeutic challenge for the physician and a debilitating illness for the patient. Genetic and immunologic advances have increased our understanding of the pathophysiology of psoriasis and psoriatic arthritis and there is a need for practically oriented evidence based references to describe the management options open to clinicians. The speed at which developments are occurring in the field also necessitates a novel approach to keeping up with these changes in practice and the need is for a reference that that be updated regularly as the subject requires. Psoriasis is an incredibly fast-moving discipline within dermatology. Guidelines, treatment options and management all change at incredible speed. There is a requirement to provide a comprehensive reference resource to provide practical, user friendly information for the dermatology profession to aid in the decision-making process. Psoriasis is a graphical subdiscipline of medicine and therefore this will have copious illustrations. As a fast moving discipline the emphasis must be on annual updates to ensure that readers are kept up to date on the important areas of development.
1447144325 9781447144328
= 12 weeks acid acitretin activity adalimumab adverse events agents alefacept Ann Rheum antibody Arch Dermatol Arthritis Rheum assessment associated baseline biologic calcipotriene calcipotriol cardiovascular cells chronic plaque psoriasis Clin clinical trials cohort compared corticosteroids cutaneous cyclosporine cytokines decreased Department of Dermatology Dermatology disease dose double-blind drug efalizumab Efficacy and safety etanercept evaluation golimumab Gottlieb guidelines hydroxyurea improvement increased risk infections inflammation inflammatory infliximab inhibit inhibitor Invest Dermatol keratinocytes laser Lebwohl leflunomide liver malignancies medication ment Menter metabolic syndrome methotrexate mg/kg moderate to severe moderate-to-severe necrosis factor obesity oral palmoplantar PASI 75 patients receiving patients treated patients with moderate patients with psoriasis phase phototherapy placebo placebo-controlled psoriasis and psoriatic psoriasis patients psoriatic arthritis PUVA randomized receptor reported response retinoid rheumatoid arthritis Rheumatol riasis severe psoriasis side effects steroids T-cell tacrolimus tazarotene tion topical treatment of psoriasis ustekinumab vitamin D week 12
-- Medical › Dermatology -- Medical / Clinical Medicine-- Medical / Dermatology